Compounds > naphthalimides
Page last updated: 2024-08-24

naphthalimides and ER-Negative PR-Negative HER2-Negative Breast Cancer

naphthalimides has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
De Iuliis, GN; Gilbert, J; McCluskey, A; Sakoff, JA1
Barron, GA; Bermano, G; Goua, M; Iwai, S; Kong Thoo Lin, P; Kuraoka, I1

Other Studies

2 other study(ies) available for naphthalimides and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway.
    Scientific reports, 2020, 08-19, Volume: 10, Issue:1

    Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; DNA Damage; Enzyme Induction; Female; HT29 Cells; Humans; MCF-7 Cells; Molecular Structure; Naphthalimides; Receptors, Aryl Hydrocarbon; Signal Transduction; Triple Negative Breast Neoplasms

2020
Bisnaphthalimidopropyl diaminodicyclohexylmethane induces DNA damage and repair instability in triple negative breast cancer cells via p21 expression.
    Chemico-biological interactions, 2015, Dec-05, Volume: 242

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclohexylamines; DNA Breaks; DNA Damage; DNA Repair; Gene Expression Regulation, Neoplastic; Humans; Naphthalimides; Triple Negative Breast Neoplasms

2015